Balterra Women's Creatine Review: Label and Cost
A skeptical label-and-evidence read of 5g creatine monohydrate plus 300mg shatavari, with no guesswork about what remains unproven.
| Dose fit | Creatine dose matches common maintenance dosing and doses used in postmenopausal-woman trials. Shatavari dose matches some 300mg studies, but this product's extract identity is not stated, so study transfer is uncertain. |
|---|---|
| Evidence fit | Creatine evidence is relevant but mostly for strength/lean mass with resistance training in postmenopausal women, not general perimenopause symptoms. Shatavari has small, short trials using specified extracts; no trial of this finished product was found. |
| Safety flags | Creatine can raise serum creatinine and cause early water-weight gain; ask a clinician about kidney disease or medicines. Shatavari long-term safety and relevance with hormone-sensitive conditions or hormone therapy are not established by the finished product data. |
| The negative case | You pay a large creatine premium, cannot verify that the shatavari extract matches study material, and are buying one bottle based only on brand claims; no independent product review was found. |
Balterra Women’s Creatine review: a clear label, uneven evidence
If the supplement aisle has started to feel like a men’s gym with pink packaging, your irritation is reasonable. A product can say “made for women” without giving women a better reason to buy it.
Balterra Women’s Creatine + Shatavari is easier to take seriously than the pink-packet crowd. The doses are printed, the serving count is clear, and the brand openly says the product is not a menopause treatment. But one important piece is missing: the shatavari extract is not identified well enough to connect this bottle to the studies.
This is a label-and-evidence first look. PeriProof did not test or take the powder, and we found no independent review of the finished product.
What Balterra claims
On its current product page, Balterra says the formula is “built for strength, recovery, and midlife balance.” It promises support for strength, recovery, muscle performance, cellular energy and women’s midlife wellness.
The page also draws a useful line: creatine is not a menopause treatment, and the product is not intended to manage hot flashes, night sweats, mood or sleep. That is a marketing claim, not proof. Supplement structure/function claims have not been evaluated by the FDA.
Still, the boundary helps. The brand says it contains no estrogen, progesterone or DHEA. That does not make the botanical automatically hormone-neutral or risk-free.
Label check: 5g is solid; the extract is not
One serving lists 5g creatine monohydrate, 300mg shatavari (Asparagus racemosus) root extract, vanilla, monk fruit and 30 servings.
The creatine dose is easy to place. The NIH Office of Dietary Supplements says monohydrate is the most studied form, commonly used at 3–5g daily. It mainly helps repeated short, intense efforts.
Shatavari is harder. Extracts are not interchangeable. One recent perimenopause trial used a 13:1 root extract standardized to more than 10% total shatavarins. Other trials used different ratios and markers. Balterra does not publish the ratio, standardization marker or a certificate of analysis in the material reviewed here.
“300mg shatavari root extract” is a quantity, not an identity.
What transfers to women 40+?
For creatine, some evidence transfers reasonably well. A 2025 systematic review of seven randomized trials involving 608 postmenopausal women found a small average lean-mass gain of 0.37kg and improved leg-press strength. Benefits were clearest with at least 5g daily plus resistance training. The authors called the gains small but meaningful. Bone-density results were not convincing.
Our creatine and perimenopause explainer covers the limits in more detail. The key one is simple: this is an exercise supplement. There is no solid basis here for turning 5g of creatine into an all-purpose anti-aging or menopause formula.
For shatavari, the transfer is shakier. A 2025 randomized perimenopause study gave 300mg of a specified standardized root extract daily for eight weeks and reported improvements in menopause symptom scores, stress, and hot-flash frequency. But it was one small, single-site study with 73 completers and only eight weeks of follow-up. A separate 2025 randomized trial also used 300mg of a specified extract for eight weeks. Several outcomes were trends rather than clear between-group wins, and the extract differed from the first study’s.
Neither trial tested Balterra’s powder. No relevant study of this finished product was found. Ingredient evidence can suggest a direction; it cannot certify this scoop.
The negative case
You are paying a steep convenience premium for a two-ingredient combination whose better-studied half is sold by Balterra on its own.
Creatine may add early water weight and raise serum creatinine without meaning kidney injury. Ask a clinician before use with kidney disease or medicines.
Shatavari needs a wider safety conversation. The short trials reported few or no adverse events, but do not settle long-term use. One trial excluded people with a history of breast or cervical cancer. Shatavari is being studied for effects on endocrine pathways. “No hormones on the label” cannot answer hormone-sensitive history, medication interactions or cancer-related concerns.
The combination also hides attribution. If training output or mood shifts, you will not know which ingredient mattered.
The real cost
At $79.99 for 30 servings, Balterra works out to:
- $2.67 per serving
- about $80.02 per 30-day month
Balterra’s standalone creatine is $42.99 for 100 servings, or $0.43 per serving. Buying 30 servings of that product costs about $12.90. The combo therefore costs $67.09 more per month. A separate verified shatavari price was not established, so the full saving from splitting products cannot honestly be calculated.
We found no product-page subscription option, discounted subscription price, renewal terms or cancellation terms. That does not mean subscriptions do not exist. It means none were verified for this review, and checkout terms should be checked before ordering. Balterra’s public return policy says eligible orders may be requested for return within 30 days of delivery; opened food or supplement returns may face exceptions, so read the current terms.
Receipts: what we could and could not verify
- Claimed: strength, recovery, muscle performance, cellular energy and midlife wellness.
- On label: 5g creatine monohydrate plus 300mg shatavari root extract, 30 servings.
- Dose fit: good common maintenance match for creatine; shatavari dose matches some studies, but extract identity is missing.
- Evidence fit: relevant creatine evidence in postmenopausal women doing resistance training. Newer, small shatavari studies do not prove this finished product.
- Safety flags: possible early water gain and raised serum creatinine from creatine; long-term shatavari safety and hormone-sensitive-use questions remain open.
- Real cost: $2.67 per day; no subscription terms verified.
- Negative case: a $67.09 monthly premium over Balterra’s standalone creatine, with no public independent review or extract-standardization receipt.
What we still don’t know
We could not verify third-party potency testing for this exact powder, the shatavari extraction ratio, or whether the finished blend matches study materials. We found no independent review and no published safety or efficacy study of Balterra Women’s Creatine itself.
Our shatavari and perimenopause explainer explains why extract specifications matter and what questions to ask a clinician. If you only want the better-supported training ingredient, plain creatine is the cleaner choice. If you want both and accept the unknowns, the label is honest about what it contains. It is just not specific enough to promise that the shatavari matches the research.
This is a label-and-evidence read, not medical advice. It does not replace care for symptoms, hormone-sensitive conditions or medication questions.